CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor
Authors:
- Maik SteinMSMaik Stein
- Petra ReinkePRPetra Reinke
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (10) , e315-e325
Abstract
Detectable CMV-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed to an absence of circulating antibodies despite CMV-sensitization. The diagnostic value of CMV-specific T cells, however, needs to be implemented in risk stratification for CMV-replication. 326 KTRs were studied and classified with respect to CMV-serostatus and presence of CMV-specific T cells. Samples were collected pretransplantation, at +1, +2, and +3 months posttransplantation. CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-γ Elispot assay. 19/67 D+R- KTRs (28%) showed pretransplant CMV-specific T cells. Although no differences were observed for CMV-replication, KTRs with CMV-specific T cells presented with lower initial and peak CMV-loads (p<0.05). KTRs with decreasing/undetectable CMV-IE1-specific T cells pre and posttransplantation were at greatest risk of CMV-replication. KTRs with stable/increasing CMV-IE1-specific T cells from pre to posttransplantation, however, showed low risk of CMV-replication (p<0.001). 162/203 R+ KTRs (80%) showed pretransplant CMV-specific T cells. Decreasing/undetectable CMV-IE1-specific T cells from pre and posttransplantation identified those R+ KTRs at increased risk of CMV-replication (65/80 KTRs; 81%; p<0.001). Despite CMV-prophylaxis, D+R- KTRs are at greatest risk of CMV-disease. Our data suggest that monitoring CMV-specific T cell kinetics from pre to posttransplantation, particularly directed to CMV-IE1, offers superior risk stratification compared to CMV-serostatus alone.Keywords
This publication has 32 references indexed in Scilit:
- High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft functionTransplant Immunology, 2009
- Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High-Level Replication After Renal TransplantationAmerican Journal of Transplantation, 2008
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsJournal of Experimental Medicine, 2005
- Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus diseaseJournal of Experimental Medicine, 2005
- ForewordAmerican Journal of Transplantation, 2004
- A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half Dose) for Preemptive Therapy of Cytomegalovirus Infection in Transplant RecipientsThe Journal of Infectious Diseases, 2004
- Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analysesTransplant International, 2000
- A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1Transplantation, 2000
- Clinical Course of Cytomegalovirus (CMV) Viremia with and without Ganciclovir Treatment in CMV-Seropositive Kidney Transplant RecipientsAmerican Journal of Nephrology, 1998
- Late-acute renal allograft rejection and symptomless cytomegalovirus infectionThe Lancet, 1994